A5058344307- Cancer Genomics and Diagnostics
- Viral-associated cancers and disorders
- Head and Neck Cancer Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Head and Neck Surgical Oncology
- Medical Imaging Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Prenatal Screening and Diagnostics
- Sinusitis and nasal conditions
- Hemoglobinopathies and Related Disorders
- MRI in cancer diagnosis
- Renal Transplantation Outcomes and Treatments
- Pancreatic and Hepatic Oncology Research
- Lymphoma Diagnosis and Treatment
- Oral and Maxillofacial Pathology
- Single-cell and spatial transcriptomics
- Mycobacterium research and diagnosis
Chinese University of Hong Kong
2017-2025
Prince of Wales Hospital
2017-2025
Circulating cell-free Epstein-Barr virus (EBV) DNA is a biomarker for nasopharyngeal carcinoma. We conducted prospective study to investigate whether EBV in plasma samples would be useful screen early carcinoma asymptomatic persons.We analyzed specimens participants who did not have symptoms of Participants with initially positive results were retested approximately 4 weeks later, and those persistently underwent nasal endoscopic examination magnetic resonance imaging (MRI).A total 20,174...
Early-stage nasopharyngeal carcinoma (NPC) evades detection when the primary tumor is hidden from view on endoscopic examination. Therefore, in a prospective study of subjects being screened for NPC using plasma Epstein-Barr virus (EBV) DNA, we conducted to investigate whether magnetic resonance imaging (MRI) could detect endoscopically occult NPC.Participants with persistently positive EBV DNA underwent examination and biopsy suspicious NPC, followed by MRI blinded findings. Participants...
Abstract Background Although contrast-enhanced magnetic resonance imaging (MRI) detects early-stage nasopharyngeal carcinoma (NPC) not detected by endoscopic-guided biopsy (EGB), a short contrast-free screening MRI would be desirable for NPC programs. This study evaluated in plasma Epstein–Barr virus (EBV)-DNA program. Methods EBV-DNA-screen-positive patients underwent endoscopy, and endoscopy-positive EGB. EGB was negative if the or performed. Patients also MRI. Diagnostic performance based...
BackgroundWe previously conducted a prospective study to show that nasopharyngeal cancer (NPC) screening with circulating Epstein–Barr virus (EBV) DNA analysis can improve survival. However, the long-term significance of positive results in individuals without was unclear.MethodsWe second-round at median 43 months after initial screening. Participants detectable plasma EBV were retested 4 weeks, and those persistently investigated nasal endoscopy magnetic resonance imaging.ResultsOf 20,174...
Fragmentomics analysis of plasma autosomal DNA has shown promise in cancer diagnostics. Here we evaluated the clinical utility Epstein-Barr virus (EBV) fragmentomics for nasopharyngeal carcinoma (NPC) screening. Among our prospective cohort approximately 20,000 subjects that underwent two rounds screening, analyzed first-round blood samples who tested positive EBV via polymerase chain reaction (PCR) (n = 558). We found those subsequently developed NPC second round exhibited a distinctive...
Background/Objectives: The detection of unknown primary tumours in the palatine tonsils (PTs) on imaging relies heavily asymmetry size between right and left sides, but expected normal range is not well documented. This study aimed to document PTs adults without cancer. Methods: retrospective evaluated 250 pairs MRIs head neck (volume, V) sides were measured, percentage difference volume (ΔV%) two was calculated. An additional analysis PT volumes 29 patients with ipsilateral early-stage...
We evaluated modifications to our contrast-enhanced MR imaging grading system for symptomatic patients with suspected nasopharyngeal carcinoma, aimed at improving discrimination of early-stage cancer and benign hyperplasia. a second non-contrast-enhanced asymptomatic from carcinoma plasma screening programs.Dedicated before (plain scan system) after intravenous contrast administration (current modified systems) was reviewed in carcinoma-endemic region, comprising 383 disease without...
Abstract Background Nuclear-derived cell-free DNA (cfDNA) molecules in blood plasma are nonrandomly fragmented, bearing a wealth of information related to tissues origin. DNASE1L3 (deoxyribonuclease 1 like 3) is an important player shaping the fragmentation nuclear-derived cfDNA molecules, preferentially generating with 5 CC dinucleotide termini (i.e., CC-end motif). However, fragment end properties microbial and its clinical implication remain be explored. Methods We performed motif...
Abstract The tissues of origin plasma DNA can be revealed by methylation patterns. However, the relative contributions from megakaryocytes and erythroblasts into appeared inconsistent among studies. To shed light this phenomenon, we developed droplet digital PCR (ddPCR) assays for differential detection these cell types in based on megakaryocyte-specific erythroblast-specific markers. Megakaryocytic erythroid contributed a median 44.2% 6.2% healthy individuals, respectively. Patients with...
The concentration of circulating cell-free DNA (cfDNA) in plasma is an important determinant the robustness liquid biopsies. However, biological mechanisms that lead to inter-individual differences cfDNA concentrations remain unexplored. governed by interplay between its release and clearance. We hypothesize clearance nucleases might be one mechanism contributes towards variations concentrations. performed fragmentomic analysis from 862 healthy individuals, with a range 1.61 - 41.01 ng/mL....